Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

 April 23, 2026

BioSpace

This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.

Clinical DataNeuroscienceRead full story

Post navigation

Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care →
← Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com